Sandoz has signed an agreement to acquire the US biosimilar ranibizumab CIMERLI® (ranibizumab-eqrn) from Coherus BioSciences, for an upfront cash purchase payment of USD 170 million. This agreement is inclusive of a biologics license application, product inventory, ophthalmology sales and…
Sandoz, the global leader in generic and biosimilar medicines, today announces the launch of Hyrimoz® (adalimumab) citrate-free high concentration formulation (HCF; 100 mg/mL) in Europe. The medicine will become available to patients progressively across European markets, starting today. Hyrimoz® HCF,…
Sandoz, the global leader in generic and biosimilar medicines, has opened two new European facilities, in line with its ongoing plans to strengthen sustainable development and supply of critical medicines in Europe and beyond. The inauguration of a new facility…